Topics

Empirico to use Precision Insights Platform to identify antisense targets for Ionis

14:40 EST 15 Jan 2020 | Elsevier Business Intelligence

Empirico Inc. signed a three-year deal to identify targets for indications and tissues of interest to Ionis Pharmaceuticals I...

Original Article: Empirico to use Precision Insights Platform to identify antisense targets for Ionis

NEXT ARTICLE

More From BioPortfolio on "Empirico to use Precision Insights Platform to identify antisense targets for Ionis"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...